Page 92 - The Flying Publisher Guide to Hepatitis C Treatment

92 | Hepatitis C Treatment

Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict
outcomes in recipients with HCV infection: results of the NIDDK Liver
transplantation database. Liver Transpl 2004;10:1120-30.
Chevaliez S, Bouvier-Alias M, Brillet R, et al. Hepatitis C virus (HCV) genotype 1
subtype identification in new HCV drug development and future clinical
practice. PLoS One 2009;4:e8209.
Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and
ribavirin in HCV infection with genotype 2 and 3 for 14 weeks: a pilot
study. Hepatology 2004;40:1260-5.
Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of
chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8.
De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG.
Novel controlled-release Lemna-derived IFN-alpha2b (Locteron):
pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical
J Interferon Cytokine Res 2008;28:113-22.
De Martin E, Senzolo M, Gambato M, et al. Fibrosis Progression and the Pros and
Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver
Transplantation: A Review. Transplantation Proceedings 2010;42:2223-5
de Leuw P, Sarrazin C, Zeuzem S. How to use virological tools for the optimal
management of chronic hepatitis C. Liver Int 2011;Suppl1:3-12.
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of
chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-
20.
Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after
peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus
ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat
2007;14:721-9.
Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced
chronic hepatitis C with low-dose peginterferon. N Engl J Med
2008;359:2429-41.
Dieterich DT, Rizzetto M, Manns MP. Management of chronic hepatitis C patients
who have relapsed or not responded to pegylated interferon alfa plus
ribavirin. J Viral Hepat 2009;16:833-43.
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and
monitoring of hepatic injury. II. Recommendations for use of laboratory
tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68.
El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to
therapy. World J Gastroenterol 2009;15:4993-9.
Everson G, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a
low accelerating dosage regimen of antiviral therapy. Hepatology
2005;42:255-62.
Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis
C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat
2008;15:79-88.
Fabrizi F, Lunghi G, Ganeshan V, et al. Hepatitis C virus infection and the dialysis
patient. Semin Dial 2007;20:416-22.